Compare CAH & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAH | NTRA |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.6B | 47.4B |
| IPO Year | 1994 | 2015 |
| Metric | CAH | NTRA |
|---|---|---|
| Price | $222.49 | $417.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $232.27 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 12.09 | 0.65 |
| EPS | ★ 7.23 | N/A |
| Revenue | ★ $254,248,000,000.00 | $210,939,000.00 |
| Revenue This Year | $17.36 | $18.08 |
| Revenue Next Year | $9.06 | $19.65 |
| P/E Ratio | $30.70 | ★ N/A |
| Revenue Growth | ★ 14.23 | N/A |
| 52 Week Low | $150.78 | $157.43 |
| 52 Week High | $258.30 | $421.64 |
| Indicator | CAH | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 36.63 | 83.32 |
| Support Level | $220.37 | $187.64 |
| Resistance Level | $222.58 | N/A |
| Average True Range (ATR) | 4.91 | 13.40 |
| MACD | -1.39 | 5.24 |
| Stochastic Oscillator | 20.69 | 90.98 |
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.